| __timestamp | Corcept Therapeutics Incorporated | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 15746000 |
| Thursday, January 1, 2015 | 36949000 | 13392000 |
| Friday, January 1, 2016 | 45240000 | 9290000 |
| Sunday, January 1, 2017 | 62416000 | 7672000 |
| Monday, January 1, 2018 | 81289000 | 15293000 |
| Tuesday, January 1, 2019 | 100359000 | 22648000 |
| Wednesday, January 1, 2020 | 105326000 | 21864000 |
| Friday, January 1, 2021 | 122356000 | 37318000 |
| Saturday, January 1, 2022 | 152848000 | 48130000 |
| Sunday, January 1, 2023 | 184259000 | 108146000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Corcept Therapeutics Incorporated and Madrigal Pharmaceuticals, Inc. have demonstrated contrasting approaches.
From 2014 to 2023, Corcept Therapeutics has consistently increased its SG&A expenses, growing by over 400%. This reflects a robust investment in administrative capabilities and market expansion. In contrast, Madrigal Pharmaceuticals, while also increasing its SG&A spending, has shown a more conservative growth of approximately 600%, indicating a strategic focus on operational efficiency.
The year 2023 marks a significant milestone, with Madrigal's SG&A expenses reaching nearly 60% of Corcept's, highlighting its aggressive push in the market. These spending patterns not only reveal the companies' strategic priorities but also offer insights into their future growth trajectories.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs MorphoSys AG Trends and Insights
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.